Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

107.43
+0.43000.40%
Volume:263.67K
Turnover:28.27M
Market Cap:12.19B
PE:31.76
High:108.17
Open:107.96
Low:106.34
Close:107.00
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.40
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:84.94
PE(LYR):41.96

Loading ...

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through at Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for Ipay 2029

THOMSON REUTERS
·
Jun 15

Halozyme names Darren Snellgrove SVP, CFO in initial beneficial ownership filing

Reuters
·
Jun 10

Halozyme CEO Helen Torley disposes of USD 2.98 million in common shares

Reuters
·
Jun 04

Halozyme publishes 2025 greenhouse gas accounting summary report

Reuters
·
Jun 04

Yang Delong: Allocating to Technology and HALO Assets, Focusing on Opportunities in the "Six Major Tracks"

Deep News
·
Jun 03

Halozyme director Bernadette Connaughton sells 1,625 shares worth $107,591.25

Reuters
·
Jun 03

Averin Capital Acquisition names Akiko Moni Miyashita to board

Reuters
·
May 30

Potential End to Current Market Rally Hinges on Strait of Hormuz, Says Sinolink Securities

Stock News
·
May 24

J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Halozyme Therapeutics Inc : JP Morgan Resumes Coverage With Neutral Rating; Price Target $70

THOMSON REUTERS
·
May 20

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

GlobeNewswire
·
May 19

These 10 'HALO' stocks protect your portfolio from the AI bubble

Dow Jones
·
May 16

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)

TIPRANKS
·
May 14

Stock Track | Halozyme Therapeutics Plummets 5.03% Intraday Amid Margin Compression and Earnings Volatility Concerns

Stock Track
·
May 14

Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative

Simply Wall St.
·
May 13

Halozyme Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 13

Halozyme price target lowered to $93 from $96 at Morgan Stanley

TIPRANKS
·
May 13

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

MT Newswires Live
·
May 12

These 10 'HALO' stocks protect your portfolio from the AI bubble

Dow Jones
·
May 12